Summary by Moomoo AI
According to the mid-year report of Triatoma-B in 2024, the company recorded a loss of RMB 95.1 million for the six months ended June 30, 2024, a significant decrease from a profit of RMB 650.6 million in the same period last year. Revenue for the period was negative RMB 10.1 million, mainly due to the return of sales of the quadrivalent influenza vaccine AdimFlu-S. Other income and gains decreased significantly to RMB 67.1 million, mainly because the funds received from CEPI were recognized as other income in 2023. Research and development expenses decreased to RMB 98.3 million, as the related research and development activities for SCB-2019 (CpG 1018/aluminum adjuvant) have been completed. The total comprehensive loss for the period was RMB 107.8 million. As of June 30, 2024, the company had cash and cash equivalents of RMB 458.8 million.
